INCY Incyte Corporation

148.52
+1  (0%)
Previous Close 147.96
Open 147.61
Price To book 66.62
Market Cap 28.13B
Shares 189,408,000
Volume 1,745,180
Short Ratio 1.02
Av. Daily Volume 2,360,130

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved November 16, 2011.
Jakafi
Myelofibrosis
Pivotal program expected to begin in 2017.
Itacitinib (JAK1)
Treatment-naïve acute GVHD
Phase 3 trial to be initiated in 2017.
Baricitinib
Psoriatic arthritis
Phase 2 expected to begin in 1H 2017.
INCB50465 (CITADEL-202)
Diffuse large B cell lymphoma
Pivotal program to commence in 2017.
Ruxolitinib
Essential thrombocythemia
Phase 3 trial to commence in 2017.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 trial to commence in 2017.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 3 planned.
Epacadostat with Keytruda
Squamous cell carcinoma of the head and neck cancer
Phase 3 planned.
Epacadostat with Keytruda
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Announced January 19 2016 NDA filing by partner Eli Lilly. Noted January 13 2017 that its PDUFA date has been extended three months. Estimate April 14, 2017.
Baricitinib
Rheumatoid arthritis
Phase 2 initiated October 2015
Ruxolitinib cream
Topical treatment of alopecia areata
Phase 3 initiated June 2016. Initial data due 2018
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 1/2 in combination with osimertinib (EGFR) expected to initiate 4Q 2016.
INCB39110 with osimertinib (EGFR)
Lung cancer
Ongoing
Epacadostat
Cancer - multiple tumor types
Approved December 4, 2014.
Jakafi (ruxolitinib) (RESPONSE)
Polycythemia Vera
Endpoint not met, mid-2014
Jakafi (ruxolitinib) (RELIEF)
Disease-related symptoms in patients with Polycythemia Vera
Phase 2 trial stopped January 2016 due to lack of efficacy
Ruxolitinib
Colorectal cancer
Phase 3 trial discontinued due to lack of efficacy
Ruxolitinib - JANUS 1 and JANUS 2
Cancer - Pancreatic
Phase 3 to be initiated 4Q 2016.
Ruxolitinib
Graft versus host disease